453 results on '"Woodruff, TK"'
Search Results
2. Pediatric oncofertility care in limited versus optimum resource settings: results from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
- Author
-
Salama, M, primary, Nahata, L., additional, Jayasinghe, Y., additional, Gomez-Lobo, V., additional, Laronda, MM., additional, Moravek, MB., additional, Meacham, LR., additional, Christianson, MS., additional, Lambertini, M., additional, Anazodo, A., additional, Quinn, GP., additional, and Woodruff, TK., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
- Author
-
Salama, M, Lambertini, M, Christianson, MS, Jayasinghe, Y, Anazodo, A, De Vos, M, Amant, F, Stern, C, Appiah, L, Woodard, TL, Anderson, RA, Westphal, LM, Leach, RE, Rodriguez-Wallberg, KA, Patrizio, P, Woodruff, TK, Salama, M, Lambertini, M, Christianson, MS, Jayasinghe, Y, Anazodo, A, De Vos, M, Amant, F, Stern, C, Appiah, L, Woodard, TL, Anderson, RA, Westphal, LM, Leach, RE, Rodriguez-Wallberg, KA, Patrizio, P, and Woodruff, TK
- Abstract
PURPOSE: As a further step to elucidate the actual diverse spectrum of oncofertility practices for breast cancer around the globe, we present and discuss the comparisons of oncofertility practices for breast cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II. METHODS: We surveyed 39 oncofertility centers including 14 in limited resource settings from Africa, Asia & Latin America (Repro-Can-OPEN Study Part I), and 25 in optimum resource settings from the United States, Europe, Australia and Japan (Repro-Can-OPEN Study Part II). Survey questions covered the availability of fertility preservation and restoration options offered to young female patients with breast cancer as well as the degree of utilization. RESULTS: In the Repro-Can-OPEN Study Part I & II, responses for breast cancer and calculated oncofertility scores showed the following characteristics: (1) higher oncofertility scores in optimum resource settings than in limited resource settings especially for established options, (2) frequent utilization of egg freezing, embryo freezing, ovarian tissue freezing, GnRH analogs, and fractionation of chemo- and radiotherapy, (3) promising utilization of oocyte in vitro maturation (IVM), (4) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, and stem cells reproductive technology as they are still in preclinical or early clinical research settings, (5) recognition that technical and ethical concerns should be considered when offering advanced and innovative oncofertility options. CONCLUSIONS: We presented a plausible oncofertility best practice model to guide oncofertility teams in optimizing care for breast cancer patients in various resource settings.
- Published
- 2022
4. A View from the past into our collective future: the oncofertility consortium vision statement
- Author
-
Woodruff, TK, Ataman-Millhouse, L, Acharya, KS, Almeida-Santos, T, Anazodo, A, Anderson, RA, Appiah, L, Bader, J, Becktell, K, Brannigan, RE, Breech, L, Bourlon, MT, Bumbuliene, Z, Burns, K, Campo-Engelstein, L, Campos, JR, Centola, GM, Chehin, MB, Chen, D, De Vos, M, Duncan, FE, El-Damen, A, Fair, D, Famuyiwa, Y, Fechner, PY, Fontoura, P, Frias, O, Gerkowicz, SA, Ginsberg, J, Gracia, CR, Goldman, K, Gomez-Lobo, V, Hazelrigg, B, Hsieh, MH, Hoyos, LR, Hoyos-Martinez, A, Jach, R, Jassem, J, Javed, M, Jayasinghe, Y, Jeelani, R, Jeruss, JS, Kaul-Mahajan, N, Keim-Malpass, J, Ketterl, TG, Khrouf, M, Kimelman, D, Kusuhara, A, Kutteh, WH, Laronda, MM, Lee, JR, Lehmann, V, Letourneau, JM, McGinnis, LK, McMahon, E, Meacham, LR, Mijangos, MFV, Moravek, M, Nahata, L, Ogweno, GM, Orwig, KE, Pavone, ME, Peccatori, FA, Pesce, RI, Pulaski, H, Quinn, G, Quintana, R, Quintana, T, de Carvalho, BR, Ramsey-Goldman, R, Reinecke, J, Reis, FM, Rios, J, Rhoton-Vlasak, AS, Rodriguez-Wallberg, KA, Roeca, C, Rotz, SJ, Rowell, E, Salama, M, Saraf, AJ, Scarella, A, Schafer-Kalkhoff, T, Schmidt, D, Senapati, S, Shah, D, Shikanov, A, Shnorhavorian, M, Skiles, JL, Smith, JF, Smith, K, Sobral, F, Stimpert, K, Su, HI, Sugimoto, K, Suzuki, N, Thakur, M, Victorson, D, Viale, L, Vitek, W, Wallace, WH, Wartella, EA, Westphal, LM, Whiteside, S, Wilcox, LH, Wyns, C, Xiao, S, Xu, J, Zelinski, M, Woodruff, TK, Ataman-Millhouse, L, Acharya, KS, Almeida-Santos, T, Anazodo, A, Anderson, RA, Appiah, L, Bader, J, Becktell, K, Brannigan, RE, Breech, L, Bourlon, MT, Bumbuliene, Z, Burns, K, Campo-Engelstein, L, Campos, JR, Centola, GM, Chehin, MB, Chen, D, De Vos, M, Duncan, FE, El-Damen, A, Fair, D, Famuyiwa, Y, Fechner, PY, Fontoura, P, Frias, O, Gerkowicz, SA, Ginsberg, J, Gracia, CR, Goldman, K, Gomez-Lobo, V, Hazelrigg, B, Hsieh, MH, Hoyos, LR, Hoyos-Martinez, A, Jach, R, Jassem, J, Javed, M, Jayasinghe, Y, Jeelani, R, Jeruss, JS, Kaul-Mahajan, N, Keim-Malpass, J, Ketterl, TG, Khrouf, M, Kimelman, D, Kusuhara, A, Kutteh, WH, Laronda, MM, Lee, JR, Lehmann, V, Letourneau, JM, McGinnis, LK, McMahon, E, Meacham, LR, Mijangos, MFV, Moravek, M, Nahata, L, Ogweno, GM, Orwig, KE, Pavone, ME, Peccatori, FA, Pesce, RI, Pulaski, H, Quinn, G, Quintana, R, Quintana, T, de Carvalho, BR, Ramsey-Goldman, R, Reinecke, J, Reis, FM, Rios, J, Rhoton-Vlasak, AS, Rodriguez-Wallberg, KA, Roeca, C, Rotz, SJ, Rowell, E, Salama, M, Saraf, AJ, Scarella, A, Schafer-Kalkhoff, T, Schmidt, D, Senapati, S, Shah, D, Shikanov, A, Shnorhavorian, M, Skiles, JL, Smith, JF, Smith, K, Sobral, F, Stimpert, K, Su, HI, Sugimoto, K, Suzuki, N, Thakur, M, Victorson, D, Viale, L, Vitek, W, Wallace, WH, Wartella, EA, Westphal, LM, Whiteside, S, Wilcox, LH, Wyns, C, Xiao, S, Xu, J, and Zelinski, M
- Abstract
PURPOSE: Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium. METHODS: The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process. RESULTS: This interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity. CONCLUSION: The goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.
- Published
- 2021
5. Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion
- Author
-
Salama, M, Woodruff, TK, Salama, M, and Woodruff, TK
- Abstract
PURPOSE: The main objective of Repro-Can-OPEN Study Part 2 is to learn more about oncofertility practices in optimum resource settings to provide a roadmap to establish oncofertility best practice models. METHODS: As an extrapolation for oncofertility best practice models in optimum resource settings, we surveyed 25 leading and well-resourced oncofertility centers and institutions from the USA, Europe, Australia, and Japan. The survey included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer. RESULTS: All surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed three major characteristics of oncofertility practice in optimum resource settings: (1) strong utilization of sperm freezing, egg freezing, embryo freezing, ovarian tissue freezing, gonadal shielding, and fractionation of chemo- and radiotherapy; (2) promising utilization of GnRH analogs, oophoropexy, testicular tissue freezing, and oocyte in vitro maturation (IVM); and (3) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cell reproductive technology as they are still in preclinical or early clinical research settings. Proper technical and ethical concerns should be considered when offering advanced and experimental oncofertility options to patients. CONCLUSIONS: Our Repro-Can-OPEN Study Part 2 proposed installing specific oncofertility programs for common cancers in optimum resource settings as an extrapolation for best practice models. This will provide efficient oncofertility edification and modeling to oncofertility teams and related healthcare providers around the globe and help them offer the best care possible to their patients.
- Published
- 2021
6. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
- Author
-
van der Kooi, Anne-Lotte, Mulder, RL, Hudson, MM, Kremer, LC, Skinner, R, Constine, LS, Dorp, Wendy, van Dulmen-Den Broeder, E, Falck-Winther, J, Wallace, WH, Waugh, J, Woodruff, TK, Anderson, RA, Armenian, SH, Bloemenkamp, KW, Critchley, HOD, Demoor-Goldschmidt, C, Ehrhardt, MJ, Green, DM, Grobman, WA, Iwahata, Y, Krishna, I, Laven, Joop, Levitt, G, Meacham, LR, Miller, ES, Mulders, Annemarie, Polanco, A, Ronckers, CM, Samuel, A, Walwyn, T, Levine, JM, van den Heuvel-Eibrink, M, van der Kooi, Anne-Lotte, Mulder, RL, Hudson, MM, Kremer, LC, Skinner, R, Constine, LS, Dorp, Wendy, van Dulmen-Den Broeder, E, Falck-Winther, J, Wallace, WH, Waugh, J, Woodruff, TK, Anderson, RA, Armenian, SH, Bloemenkamp, KW, Critchley, HOD, Demoor-Goldschmidt, C, Ehrhardt, MJ, Green, DM, Grobman, WA, Iwahata, Y, Krishna, I, Laven, Joop, Levitt, G, Meacham, LR, Miller, ES, Mulders, Annemarie, Polanco, A, Ronckers, CM, Samuel, A, Walwyn, T, Levine, JM, and van den Heuvel-Eibrink, M
- Abstract
Female childhood, adolescent, and young adult cancer survivors have an increased risk of adverse pregnancy outcomes related to their cancer- or treatment-associated sequelae. Optimal care for childhood, adolescent, and young adult cancer survivors can be facilitated by clinical practice guidelines that identify specific adverse pregnancy outcomes and the clinical characteristics of at-risk subgroups. However, national guidelines are scarce and vary in content. Here, the International Late Effects of Childhood Cancer Guideline Harmonization Group offers recommendations for the counseling and surveillance of obstetrical risks of childhood, adolescent, and young adult survivors. A systematic literature search in MEDLINE database (through PubMed) to identify all available evidence published between January 1990 and December 2018. Published articles on pregnancy and perinatal or congenital risks in female cancer survivors were screened for eligibility. Study designs with a sample size larger than 40 pregnancies in childhood, adolescent, and young adult cancer survivors (diagnosed before the age of 25 years, not pregnant at that time) were eligible. This guideline from the International Late Effects of Childhood Cancer Guideline Harmonization Group systematically appraised the quality of available evidence for adverse obstetrical outcomes in childhood, adolescent, and young adult cancer survivors using Grading of Recommendations Assessment, Development, and Evaluation methodology and formulated recommendations to enhance evidence-based obstetrical care and preconception counseling of female childhood, adolescent, and young adult cancer survivors. Healthcare providers should discuss the risk of adverse obstetrical outcomes based on cancer treatment exposures with all female childhood, adolescent, and young adult cancer survivors of reproductive age, before conception. Healthcare providers should be aware that there is no evidence to support an increased risk of giving b
- Published
- 2021
7. Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?
- Author
-
Nahata, L, Woodruff, TK, Quinn, GP, Meacham, LR, Chen, D, Appiah, LC, Finlayson, C, Orwig, KE, Laronda, MM, Rowell, EE, Anazodo, A, Frias, O, Rios, JS, Whiteside, S, Gomez-Lobo, V, Dwiggins, M, Childress, KJ, Hoefgen, HR, Levine, JM, Jayasinghe, Y, Moravek, M, Nahata, L, Woodruff, TK, Quinn, GP, Meacham, LR, Chen, D, Appiah, LC, Finlayson, C, Orwig, KE, Laronda, MM, Rowell, EE, Anazodo, A, Frias, O, Rios, JS, Whiteside, S, Gomez-Lobo, V, Dwiggins, M, Childress, KJ, Hoefgen, HR, Levine, JM, Jayasinghe, Y, and Moravek, M
- Published
- 2020
8. Prospects of Rescuing Young Eggs for Oncofertility
- Author
-
Bertoldo, MJ, Smitz, J, Wu, LE, Lee, HC, Woodruff, TK, Gilchrist, RB, Bertoldo, MJ, Smitz, J, Wu, LE, Lee, HC, Woodruff, TK, and Gilchrist, RB
- Abstract
Childhood cancer patients undergoing cancer therapy can be rendered infertile during adulthood. With more girls surviving cancer, fertility preservation in young cancer patients is a major clinical challenge. Advances in egg culture may offer benefits for the fertility of these patients in the future.
- Published
- 2020
9. Creating a global community of practice for oncofertility
- Author
-
Ataman, LM, Rodrigues, JK, Marinho, RM, Caetano, JPJ, Chehin, MB, Alves da Motta, EL, Serafini, P, Suzuki, N, Furui, T, Takae, S, Sugishita, Y, Morishige, KI, Almeida-Santos, T, Melo, C, Buzaglo, K, Irwin, K, Hamish Wallace, W, Anderson, RA, Mitchell, RT, Telfer, EE, Adiga, SK, Anazodo, A, Stern, C, Sullivan, E, Jayasinghe, Y, Orme, L, Cohn, R, McLachlan, R, Deans, R, Agresta, F, Gerstl, B, Ledger, WL, Robker, RL, de Meneses e Silva, JM, Melo e Silva, LHF, Lunardi, FO, Lee, JR, Suh, CS, de Vos, M, van Moer, E, Stoop, D, Vloeberghs, V, Smitz, J, Tournaye, H, Wildt, L, Winkler-Crepaz, K, Andersen, CY, Smith, BM, Smith, K, Woodruff, TK, Ataman, LM, Rodrigues, JK, Marinho, RM, Caetano, JPJ, Chehin, MB, Alves da Motta, EL, Serafini, P, Suzuki, N, Furui, T, Takae, S, Sugishita, Y, Morishige, KI, Almeida-Santos, T, Melo, C, Buzaglo, K, Irwin, K, Hamish Wallace, W, Anderson, RA, Mitchell, RT, Telfer, EE, Adiga, SK, Anazodo, A, Stern, C, Sullivan, E, Jayasinghe, Y, Orme, L, Cohn, R, McLachlan, R, Deans, R, Agresta, F, Gerstl, B, Ledger, WL, Robker, RL, de Meneses e Silva, JM, Melo e Silva, LHF, Lunardi, FO, Lee, JR, Suh, CS, de Vos, M, van Moer, E, Stoop, D, Vloeberghs, V, Smitz, J, Tournaye, H, Wildt, L, Winkler-Crepaz, K, Andersen, CY, Smith, BM, Smith, K, and Woodruff, TK
- Abstract
Fertility preservation in the cancer setting, known as oncofertility, is a field that requires cross-disciplinary interaction between physicians, basic scientists, clinical researchers, ethicists, lawyers, educators, and religious leaders. Funded by the National Institutes of Health, the Oncofertility Consortium (OC) was formed to be a scientifically grounded, transparent, and altruistic resource, both intellectual and monetary, for building this new field of practice capable of addressing the unique needs of young patients with cancer. The OC has expanded its attention to include other nonmalignant conditions that can threaten fertility, and the work of the OC now extends around the globe, involving partners who together have created a community of shared effort, resources, and practices. The OC creates materials that are translated, disseminated, and amended by all participants in the field, and local programs of excellence have developed worldwide to accelerate the pace and improve the quality of oncofertility research and practice. Here we review the global oncofertility programs and the capacity building activities that strengthen these research and clinical programs, ultimately improving patient care.
- Published
- 2020
10. Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe
- Author
-
Rashedi, AS, de Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, de Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sanchez, F, Terrado, G, Rodrigues, JK, de Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Ferreira Melo e Silva, LH, Wildt, L, Salama, M, del Mar Andres, M, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Almeida Campos-Junior, PH, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RDA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, Woodruff, TK, Rashedi, AS, de Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, de Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sanchez, F, Terrado, G, Rodrigues, JK, de Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Ferreira Melo e Silva, LH, Wildt, L, Salama, M, del Mar Andres, M, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Almeida Campos-Junior, PH, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RDA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, and Woodruff, TK
- Abstract
PURPOSE: In the accompanying article, "Analysis of Fertility Preservation Options Available to Patients With Cancer Around the Globe," we showed that specific fertility preservation services may not be offered at various sites around the world because of cultural and legal barriers. We assessed global and regional experiences as well as the legal status of third-party reproduction and adoption to serve as a comprehensive international data set and resource for groups that wish to begin oncofertility interventions. METHODS: We provide data on the legalities of third-party assisted reproductive technologies and other family-building options in the 28 oncofertility-practicing countries surveyed. RESULTS: We found regional and country differences that will be important in the development of tailored resources for physicians and for patient brochures that are sensitive to these local restrictions and cultural norms. CONCLUSION: Because many patients first consult Web-based materials, the formal assessment of the availability of these options provides members of the global oncofertility community with data to which they might otherwise not have ready access to better serve their patients.
- Published
- 2020
11. Mouse Model of Metabolic Syndrome Reveals a Negative Effect on Oocyte Quality and Quantity.
- Author
-
Hirshfeld-Cytron, JE, primary, Xu, M, additional, Josefik, JK, additional, Shea, LD, additional, and Woodruff, TK, additional
- Published
- 2010
- Full Text
- View/download PDF
12. The Steroid Metabolome in the Isolated Ovarian Follicle and Its Response to Androgen Exposure and Antagonism
- Author
-
Lebbe, M, Taylor, AE, Visser, Jenny, Kirkman-Brown, JC, Woodruff, TK, Arlt, W, and Internal Medicine
- Subjects
Reproduction, Sex, and Gender ,Dehydroepiandrosterone ,urologic and male genital diseases ,Mice ,Ovarian Follicle ,Androgen Receptor Antagonists ,Androgens ,Metabolome ,Animals ,Female ,Steroids ,Gonadal Steroid Hormones ,Research Articles ,Cells, Cultured ,Metabolic Networks and Pathways - Abstract
The ovarian follicle is a major site of steroidogenesis, crucially required for normal ovarian function and female reproduction. Our understanding of androgen synthesis and metabolism in the developing follicle has been limited by the sensitivity and specificity issues of previously used assays. Here we used liquid chromatography–tandem mass spectrometry to map the stage-dependent endogenous steroid metabolome in an encapsulated in vitro follicle growth system, from murine secondary through antral follicles. Furthermore, follicles were cultured in the presence of androgen precursors, nonaromatizable active androgen, and androgen receptor (AR) antagonists to assess effects on steroidogenesis and follicle development. Cultured follicles showed a stage-dependent increase in endogenous androgen, estrogen, and progesterone production, and incubations with the sex steroid precursor dehydroepiandrosterone revealed the follicle as capable of active androgen synthesis at early developmental stages. Androgen exposure and antagonism demonstrated AR–mediated effects on follicle growth and antrum formation that followed a biphasic pattern, with low levels of androgens inducing more rapid follicle maturation and high doses inhibiting oocyte maturation and follicle growth. Crucially, our study provides evidence for an intrafollicular feedback circuit regulating steroidogenesis, with decreased follicle androgen synthesis after exogenous androgen exposure and increased androgen output after additional AR antagonist treatment. We propose that this feedback circuit helps maintain an equilibrium of androgen exposure in the developing follicle. The observed biphasic response of follicle growth and function in increasing androgen supplementations has implications for our understanding of polycystic ovary syndrome pathophysiology and the dose-dependent utility of androgens in in vitro fertilization settings., Steroid metabolome analysis by mass spectrometry in the isolated ovarian follicle revealed early developmental capacity for androgen synthesis, which was upregulated by androgen receptor antagonists.
- Published
- 2017
13. The Development of an International Oncofertility Competency Framework: A Model to Increase Oncofertility Implementation
- Author
-
Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Chen, QH, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Sullivan, E, Ledger, W, Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Chen, QH, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Sullivan, E, and Ledger, W
- Abstract
Background: Despite international evidence about fertility preservation (FP), several barriers still prevent the implementation of equitable FP practice. Currently, oncofertility competencies do not exist. The aim of this study was to develop an oncofertility competency framework that defines the key components of oncofertility care, develops a model for prioritizing service development, and defines the roles that health care professionals (HCPs) play. Materials and Method: A quantitative modified Delphi methodology was used to conduct two rounds of an electronic survey, querying and synthesizing opinions about statements regarding oncofertility care with HCPs and patient and family advocacy groups (PFAs) from 16 countries (12 high and 4 middle income). Statements included the roles of HCPs and priorities for service development care across ten domains (communication, oncofertility decision aids, age-appropriate care, referral pathways, documentation, oncofertility training, reproductive survivorship care and fertility-related psychosocial support, supportive care, and ethical frameworks) that represent 33 different elements of care. Results: The first questionnaire was completed by 457 participants (332 HCPs and 125 PFAs). One hundred and thirty-eight participants completed the second questionnaire (122 HCPs and 16 PFAs). Consensus was agreed on 108 oncofertility competencies and the roles HCPs should play in oncofertility care. A three-tier service development model is proposed, with gradual implementation of different components of care. A total of 92.8% of the 108 agreed competencies also had agreement between high and middle income participants. Conclusion: FP guidelines establish best practice but do not consider the skills and requirements to implement these guidelines. The competency framework gives HCPs and services a structure for the training of HCPs and implementation of care, as well as defining a model for prioritizing oncofertility service development
- Published
- 2019
14. How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care
- Author
-
Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Qiong-Hua, C, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Ledger, W, Sullivan, E, Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Qiong-Hua, C, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Ledger, W, and Sullivan, E
- Abstract
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. BACKGROUND: Fertility preservation (FP) is an important quality of life issue for cancer survivors of reproductive age. Despite the existence of broad international guidelines, the delivery of oncofertility care, particularly amongst paediatric, adolescent and young adult patients, remains a challenge for healthcare professionals (HCPs). The quality of oncofertility care is variable and the uptake and utilization of FP remains low. Available guidelines fall short in providing adequate detail on how oncofertility models of care (MOC) allow for the real-world application of guidelines by HCPs. OBJECTIVE AND RATIONALE: The aim of this study was to systematically review the literature on the components of oncofertility care as defined by patient and clinician representatives, and identify the barriers, facilitators and challenges, so as to improve the implementation of oncofertility services. SEARCH METHODS: A systematic scoping review was conducted on oncofertility MOC literature published in English between 2007 and 2016, relating to 10 domains of care identified through consumer research: communication, oncofertility decision aids, age-appropriate care, referral pathways, documentation, training, supportive care during treatment, reproductive care after cancer treatment, psychosocial support and ethical practice of oncofertility care. A wide range of electronic databases (CINAHL, Embase, PsycINFO, PubMed, AEIPT, Education Research Complete, ProQuest and VOCED) were searched in order to synthesize the evidence around delivery of oncofertility care. Related citations and reference lists were searched. The review was undertaken following registration (International prospective register of systematic reviews (PROSPERO) registration number CRD42017055837) and guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRI
- Published
- 2019
15. Survey of fertility preservation options available to patients with cancer around the globe
- Author
-
Rashedi, AS, De Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, De Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sánchez, F, Terrado, G, Rodrigues, JK, De Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Melo e Silva, LHF, Wildt, L, Salama, M, Del Mar Andrés, M, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Campos-Junior, PHA, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, Woodruff, TK, Rashedi, AS, De Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, De Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sánchez, F, Terrado, G, Rodrigues, JK, De Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Melo e Silva, LHF, Wildt, L, Salama, M, Del Mar Andrés, M, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Campos-Junior, PHA, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, and Woodruff, TK
- Abstract
Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psychological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that some fertility preservation services are not offered because of cultural and legal barriers. The growth of oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding. Conclusion This survey reveals global and regional successes and challenges and provides insight into what is needed to advance the field and make the discussion of fertility preservation and endocrine health a standard component of the cancer treatment plan. As the field of oncofertility continues to develop around the globe, regular assessment of both international and regional barriers to quality care must continue to guide process improvements.
- Published
- 2018
16. Models of care in providing fertility preservation for women with cancer
- Author
-
Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Qiang-Hua, C, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Ledger, W, Sullivan, E, Anazodo, A, Laws, P, Logan, S, Saunders, C, Travaglia, J, Gerstl, B, Bradford, N, Cohn, R, Birdsall, M, Barr, R, Suzuki, N, Takae, S, Marinho, R, Xiao, S, Qiang-Hua, C, Mahajan, N, Patil, M, Gunasheela, D, Smith, K, Sender, L, Melo, C, Almeida-Santos, T, Salama, M, Appiah, L, Su, I, Lane, S, Woodruff, TK, Pacey, A, Anderson, RA, Shenfield, F, Ledger, W, and Sullivan, E
- Abstract
Background: Fertility preservation (FP) is an important quality of life issue for cancer survivors of reproductive age. Despite the existence of broad international guidelines, the delivery of oncofertility care remains a challenge for healthcare professionals (HCPs), particularly amongst paediatric, adolescent and young adult patients. The quality of oncofertility care is variable and the uptake and utilisation of FP remains low. Available guidelines fall short in providing adequate detail on how oncofertility models of care allow for the real-world application of guidelines by HCPs. Objective and rationale: To systematically review the literature on the components of oncofertility care as defined by patient and clinician representatives, and identify the barriers, facilitators and challenges so as to improve the implementation of oncofertility services. Search methods: A systematic scoping review was conducted on oncofertility models of care (MOC) literature published in English between 2007-2016, relating to ten domains of care identified through consumer research (communication, oncofertility decision aids, age appropriate care, referral pathways, documentation, training, supportive care during treatment, reproductive care after cancer treatment, psychosocial support and ethical practice of oncofertility care). A wide range of electronic databases (CINAHL, Embase, PsycINFO, PubMed, AEIPT, Education Research Complete, ProQuest and VOCED) were searched in order to synthesise the evidence around delivery of oncofertility care. Related citations and reference lists were searched. The review was undertaken following registration (International prospective register of systematic reviews (PROSPERO) registration number CRD42017055837) and guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).Outcomes: A total of 846 potentially relevant studies were identified after the removal of duplicates. All titles and abstracts were scre
- Published
- 2018
17. OncofertilityAn emerging discipline rather than a special consideration
- Author
-
Anazodo, A, Ataman-Millhouse, L, Jayasinghe, Y, Woodruff, TK, Anazodo, A, Ataman-Millhouse, L, Jayasinghe, Y, and Woodruff, TK
- Abstract
Originally absent from the oncologist's consult, then placed in a 'quality of life' rubric, oncofertility should now be an essential part of a comprehensive cancer treatment plan in patients of reproductive age, including adolescents and young adults (AYAs). Oncofertility encompasses the endocrine health of the patient, as well as fertility management options. Thus, pubertal transitions in males and females, bone health, and menstrual health are all part of this discipline, enabling practitioners to work in interdisciplinary teams to solve problems in reproductive health. This review provides a summary of the essential considerations required for the assessement of reproductive risk and choice of fertility preservation options as well as considerations for developing oncofertility services for AYAs.
- Published
- 2018
18. Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe
- Author
-
Rashedi, AS, de Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, de Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sanchez, F, Terrado, G, Rodrigues, JK, de Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Melo e Silva, LHF, Wildt, L, Salama, M, Andres, MDM, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Almeida Campos-Junior, PH, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RDA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, Woodruff, TK, Rashedi, AS, de Roo, SF, Ataman, LM, Edmonds, ME, Silva, AA, Scarella, A, Horbaczewska, A, Anazodo, A, Arvas, A, de Carvalho, BR, Sartorio, C, Beerendonk, CCM, Diaz-Garcia, C, Suh, CS, Melo, C, Andersen, CY, Motta, E, Greenblatt, EM, Van Moer, E, Zand, E, Reis, FM, Sanchez, F, Terrado, G, Rodrigues, JK, de Meneses e Silva, JM, Smitz, J, Medrano, J, Lee, JR, Winkler-Crepaz, K, Smith, K, Melo e Silva, LHF, Wildt, L, Salama, M, Andres, MDM, Bourlon, MT, Vega, M, Chehin, MB, De Vos, M, Khrouf, M, Suzuki, N, Azmy, O, Fontoura, P, Almeida Campos-Junior, PH, Mallmann, P, Azambuja, R, Marinho, RM, Anderson, RA, Jach, R, Antunes, RDA, Mitchell, R, Fathi, R, Adiga, SK, Takae, S, Kim, SH, Romero, S, Grieco, SC, Shaulov, T, Furui, T, Almeida-Santos, T, Nelen, W, Jayasinghe, Y, Sugishita, Y, and Woodruff, TK
- Abstract
PURPOSE: Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. METHODS: Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health-funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. RESULTS: Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psychological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that some fertility preservation services are not offered because of cultural and legal barriers. The growth of oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding. CONCLUSION: This survey reveals global and regional successes and challenges and provides insight into what is needed to advance the field and make the discussion of fertility preservation and endocrine health a standard component of the cancer treatment plan. As the field of oncofertility continues to develop around the globe, regular assessment of both international and regional barriers to quality care must continue to guide process improvements.
- Published
- 2017
19. Creating a Global Community of Practice for Oncofertility.
- Author
-
Ataman, LM, Rodrigues, JK, Marinho, RM, Caetano, JPJ, Chehin, MB, Alves da Motta, EL, Serafini, P, Suzuki, N, Furui, T, Takae, S, Sugishita, Y, Morishige, K-I, Almeida-Santos, T, Melo, C, Buzaglo, K, Irwin, K, Wallace, WH, Anderson, RA, Mitchell, RT, Telfer, EE, Adiga, SK, Anazodo, A, Stern, C, Sullivan, E, Jayasinghe, Y, Orme, L, Cohn, R, McLachlan, R, Deans, R, Agresta, F, Gerstl, B, Ledger, WL, Robker, RL, de Meneses E Silva, JM, Silva, LHFME, Lunardi, FO, Lee, JR, Suh, CS, De Vos, M, Van Moer, E, Stoop, D, Vloeberghs, V, Smitz, J, Tournaye, H, Wildt, L, Winkler-Crepaz, K, Andersen, CY, Smith, BM, Smith, K, Woodruff, TK, Ataman, LM, Rodrigues, JK, Marinho, RM, Caetano, JPJ, Chehin, MB, Alves da Motta, EL, Serafini, P, Suzuki, N, Furui, T, Takae, S, Sugishita, Y, Morishige, K-I, Almeida-Santos, T, Melo, C, Buzaglo, K, Irwin, K, Wallace, WH, Anderson, RA, Mitchell, RT, Telfer, EE, Adiga, SK, Anazodo, A, Stern, C, Sullivan, E, Jayasinghe, Y, Orme, L, Cohn, R, McLachlan, R, Deans, R, Agresta, F, Gerstl, B, Ledger, WL, Robker, RL, de Meneses E Silva, JM, Silva, LHFME, Lunardi, FO, Lee, JR, Suh, CS, De Vos, M, Van Moer, E, Stoop, D, Vloeberghs, V, Smitz, J, Tournaye, H, Wildt, L, Winkler-Crepaz, K, Andersen, CY, Smith, BM, Smith, K, and Woodruff, TK
- Abstract
Fertility preservation in the cancer setting, known as oncofertility, is a field that requires cross-disciplinary interaction between physicians, basic scientists, clinical researchers, ethicists, lawyers, educators, and religious leaders. Funded by the National Institutes of Health, the Oncofertility Consortium (OC) was formed to be a scientifically grounded, transparent, and altruistic resource, both intellectual and monetary, for building this new field of practice capable of addressing the unique needs of young patients with cancer. The OC has expanded its attention to include other nonmalignant conditions that can threaten fertility, and the work of the OC now extends around the globe, involving partners who together have created a community of shared effort, resources, and practices. The OC creates materials that are translated, disseminated, and amended by all participants in the field, and local programs of excellence have developed worldwide to accelerate the pace and improve the quality of oncofertility research and practice. Here we review the global oncofertility programs and the capacity building activities that strengthen these research and clinical programs, ultimately improving patient care.
- Published
- 2016
20. ES6-1: Oncofertility: Translation in Multiple Dimensions.
- Author
-
Woodruff, TK, primary
- Published
- 2011
- Full Text
- View/download PDF
21. Imaging and Elemental Mapping of Biological Specimens with the Hitachi HD-2300A Dual-EDS Scanning Transmission Electron Microscope
- Author
-
Wu, JS, primary, Kim, AM, additional, Marvin, RG, additional, Myers, BD, additional, Woodruff, TK, additional, O'Halloran, TV, additional, Dravid, VP, additional, McIlwrath, K, additional, and Li, SY, additional
- Published
- 2010
- Full Text
- View/download PDF
22. GONADOTROPIN-RELEASING-HORMONE, INBIBIN, AND ACTIVIN IN HUMAN PLACENTA - EVIDENCE FOR A COMMON CELLULAR-LOCALIZATION
- Author
-
Petraglia, Felice, Woodruff, Tk, Botticelli, G, Botticelli, A, Genazzani, Andrea Riccardo, Mayo, Ke, and Vale, W.
- Published
- 1992
23. Activin signal transduction in the fetal rat adrenal gland and in human H295R cells
- Author
-
Wang, EY, primary, Ma, EY, additional, and Woodruff, TK, additional
- Published
- 2003
- Full Text
- View/download PDF
24. Photoperiod-dependent regulation of inhibin in Siberian hamsters: I. Ovarian inhibin production and secretion
- Author
-
Kenny, HA, primary, Bernard, DJ, additional, Horton, TH, additional, and Woodruff, TK, additional
- Published
- 2002
- Full Text
- View/download PDF
25. Photoperiod-dependent regulation of inhibin in Siberian hamsters: II. Regulation of inhibin production and secretion by pregnant mare serum gonadotropin
- Author
-
Kenny, HA, primary, Bernard, DJ, additional, Horton, TH, additional, and Woodruff, TK, additional
- Published
- 2002
- Full Text
- View/download PDF
26. Production and purification of recombinant human inhibin and activin
- Author
-
Pangas, SA, primary and Woodruff, TK, additional
- Published
- 2002
- Full Text
- View/download PDF
27. Episodic secretion of activin A in pregnant women
- Author
-
Gallinelli, A, primary, Gallo, R, additional, Genazzani, AD, additional, Matteo, ML, additional, Caruso, A, additional, Woodruff, TK, additional, and Petraglia, F, additional
- Published
- 1996
- Full Text
- View/download PDF
28. Age-associated alteration of oocyte-specific gene expression in polar bodies: potential markers of oocyte competence.
- Author
-
Jiao ZX, Xu M, Woodruff TK, Jiao, Ze-Xu, Xu, Min, and Woodruff, Teresa K
- Abstract
Objective: To confirm that oocyte-specific messenger RNAs are detectable in the polar body (PB) of metaphase II (MII) oocytes and determine the effect of age on oocyte-specific transcript levels.Design: Prospective study.Setting: Hospital-based academic research laboratory.Animal(s): CD1 female mice.Intervention(s): Aged (40-50 weeks) and young (7-9 weeks) mice were administered pregnant mare serum gonadotropin (PMSG) and hCG. Oocytes were fertilized in vitro to assess fertilization and developmental competence. The MII oocytes were obtained and first PBs were removed. Messenger RNAs from each PB and its sibling oocyte were reverse transcribed and analyzed by real-time quantitative polymerase chain reaction (PCR).Main Outcome Measure(s): Fertilization and developmental rates and expression of six oocyte-specific genes (Bmp15, Gdf9, H1foo, Nlrp5, Tcl1, and Zp3) in PBs and sibling oocytes from young versus aged mice.Result(s): Oocytes from aged mice had lower developmental competence. Four genes (H1foo, Nlrp5, Tcl1, and Zp3) were differentially expressed in aged versus young oocytes. All six transcripts were present in PBs from aged and young mice at lower levels than in the sibling oocytes; transcript levels were lower in aged PBs compared with young PBs.Conclusion(s): There is a significant difference in the transcript levels of oocyte-specific genes in aged versus young PB that correlates with age-related decreases in oocyte competence. Differences in gene expression in PB may be potential biomarkers of MII oocyte competence. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
29. Follicle-intrinsic and spatially distinct molecular programs drive follicle rupture and luteinization during ex vivo mammalian ovulation.
- Author
-
Zaniker EJ, Zhang J, Russo D, Huang R, Suritis K, Drake RS, Barlow-Smith E, Shalek AK, Woodruff TK, Xiao S, Goods BA, and Duncan FE
- Subjects
- Female, Animals, Mice, Signal Transduction, Mice, Inbred C57BL, Ovulation genetics, Ovarian Follicle metabolism, Luteinization
- Abstract
During ovulation, the apical wall of the preovulatory follicle breaks down to facilitate gamete release. In parallel, the residual follicle wall differentiates into a progesterone-producing corpus luteum. Disruption of ovulation, whether through contraceptive intervention or infertility, has implications for women's health. In this study, we harness the power of an ex vivo ovulation model and machine-learning guided microdissection to identify differences between the ruptured and unruptured sides of the follicle wall. We demonstrate that the unruptured side exhibits clear markers of luteinization after ovulation while the ruptured side exhibits cell death signals. RNA-sequencing of individual follicle sides reveals 2099 differentially expressed genes (DEGs) between follicle sides without ovulation induction, and 1673 DEGs 12 h after induction of ovulation. Our model validates molecular patterns consistent with known ovulation biology even though this process occurs in the absence of the ovarian stroma, vasculature, and immune cells. We further identify previously unappreciated pathways including amino acid transport and Jag-Notch signaling on the ruptured side and glycolysis, metal ion processing, and IL-11 signaling on the unruptured side of the follicle. This study yields key insights into follicle-inherent, spatially-defined pathways that underlie follicle rupture, which may further understanding of ovulation physiology and advance women's health., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Investigation of Fertility Preservation Education Videos for Pediatric Patients Based on International and Historical Survey.
- Author
-
Iwahata Y, Takae S, Iwahata H, Matsumoto K, Hirayama M, Takita J, Manabe A, Cho Y, Ikeda T, Maezawa T, Miyachi M, Keino D, Koizumi T, Mori T, Shimizu N, Woodruff TK, and Suzuki N
- Subjects
- Humans, Child, United States, Counseling, Medical Oncology, Fertility Preservation methods, Neoplasms therapy, Infertility etiology, Infertility prevention & control
- Abstract
Purpose: Recently, direct communication with children about cancer seems to have shifted, but little is known about communication regarding discussions of future infertility risk due to cancer therapy. This study conducted cross-cultural comparisons between Japan and the United States to clarify communication patterns about cancer notification and develop appropriate information about fertility issues. Methods: An online survey was distributed to members of the Japanese Society of Pediatric Hematology/Oncology in July 2019 and the American Society of Pediatric Hematology/Oncology in July 2020. Based on the results from the survey, we developed three types of educational videos: a prepubertal version A, B, and a pubertal version. Next, we conducted a survey to assess whether these were appropriate for clinical practice. Results: We analyzed 325 physicians in Japan and 46 in the United States. In Japan, 80.5%, 91.7%, and 92.1% of the physicians notified patients aged 7-9, 10-14, and 15-17 years of their cancer diagnosis directly, respectively, compared within the United States, where the rate was 100%, regardless of age. Further, 9% and 45% of physicians in Japan and the United States, respectively, discuss fertility issues directly with patients aged 7-9 years. In the survey to assess the educational videos, 85% of the physicians preferred to use the educational videos in clinical practice. Conclusion: This is the first step in bringing concordance to communication patters for emerging cancer care around the globe and that this study and its intervention arm provide guidance in ways that ensure global equity in care.
- Published
- 2023
- Full Text
- View/download PDF
31. A new tissue-agnostic microfluidic device to model physiology and disease: the lattice platform.
- Author
-
Campo H, Zha D, Pattarawat P, Colina J, Zhang D, Murphy A, Yoon J, Russo A, Rogers HB, Lee HC, Zhang J, Trotter K, Wagner S, Ingram A, Pavone ME, Dunne SF, Boots CE, Urbanek M, Xiao S, Burdette JE, Woodruff TK, and Kim JJ
- Subjects
- Female, Animals, Humans, Mice, Microfluidics, Coculture Techniques, Polycystic Ovary Syndrome metabolism
- Abstract
To accurately phenocopy human biology in vitro , researchers have been reducing their dependence on standard, static two-dimensional (2D) cultures and instead are moving towards three-dimensional (3D) and/or multicellular culture techniques. While these culture innovations are becoming more commonplace, there is a growing body of research that illustrates the benefits and even necessity of recapitulating the dynamic flow of nutrients, gas, waste exchange and tissue interactions that occur in vivo . However, cost and engineering complexity are two main factors that hinder the adoption of these technologies and incorporation into standard laboratory workflows. We developed LATTICE, a plug-and-play microfluidic platform able to house up to eight large tissue or organ models that can be cultured individually or in an interconnected fashion. The functionality of the platform to model both healthy and diseased tissue states was demonstrated using 3D cultures of reproductive tissues including murine ovarian tissues and human fallopian tube explants (hFTE). When exogenously exposed to pathological doses of gonadotropins and androgens to mimic the endocrinology of polycystic ovarian syndrome (PCOS), subsequent ovarian follicle development, hormone production and ovulation copied key features of this endocrinopathy. Further, hFTE cilia beating decreased significantly only when experiencing continuous media exchanges. We were then able to endogenously recreate this phenotype on the platform by dynamically co-culturing the PCOS ovary and hFTE. LATTICE was designed to be customizable with flexibility in 3D culture formats and can serve as a powerful automated tool to enable the study of tissue and cellular dynamics in health and disease in all fields of research.
- Published
- 2023
- Full Text
- View/download PDF
32. National oncofertility registries around the globe: a pilot survey.
- Author
-
Ozimek N, Salama M, and Woodruff TK
- Subjects
- Humans, Australia epidemiology, Argentina, Brazil, Chile, Fertility Preservation
- Abstract
Purpose: Oncofertility is an emerging discipline which aims to preserve fertility of young cancer patients. As fertility preservation services have become increasingly available to cancer patients in many countries around the globe, it is crucial to establish a foundation of collaborative reporting to continuously monitor and assess oncofertility practices. This survey study investigates the current global landscape of official national oncofertility registries, a vital tool which allows for surveillance of the field., Methods: An online pilot survey was conducted to give the opportunity to report official national oncofertility registries available in 2022. Survey questions covered the availability of official national registries for oncofertility as well as the official national registries for cancer and assisted reproductive technologies. Participation in the survey was voluntary, anonymous and for free., Results: According to our online pilot survey, responses were collected from 20 countries including Argentina, Australia, Brazil, Canada, Chile, China, Egypt, Germany, Greece, India, Japan, Kenya, Philippines, Romania, South Africa, Thailand, Tunisia, UK, USA & Uruguay. Only 3 out of the 20 surveyed countries have well-established official national oncofertility registries; and include Australia, Germany & Japan. The Australian official national oncofertility registry is part of Australasian Oncofertility Registry that also includes New Zealand. The German official national oncofertility registry is part of FertiPROTEKT Network Registry for German speaking countries that also includes Austria & Switzerland. The Japanese official national oncofertility registry includes Japan only and called Japan Oncofertility Registry (JOFR). A supplementary internet search confirmed the aforementioned results. Therefore, the final list of countries around the globe that have official national oncofertility registries includes Australia, Austria, Germany, Japan, New Zealand, and Switzerland. Some other countries such as the USA and Denmark are on their way to establish official national registries for oncofertility care., Conclusion: Although oncofertility services are expanding globally, very few countries have well-established official national oncofertility registries. By reviewing such a global landscape, we highlight the urgent need for having a well-established official national oncofertility registry in each country to monitor oncofertility services in a way that best serves patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Ozimek, Salama and Woodruff.)
- Published
- 2023
- Full Text
- View/download PDF
33. An ex vivo ovulation system enables the discovery of novel ovulatory pathways and nonhormonal contraceptive candidates†.
- Author
-
Zhang J, Goods BA, Pattarawat P, Wang Y, Haining T, Zhang Q, Shalek AK, Duncan FE, Woodruff TK, and Xiao S
- Subjects
- Female, Humans, Animals, Mice, Ovulation physiology, Ovarian Follicle metabolism, Oogenesis, Menstrual Cycle, Progesterone pharmacology, Contraceptive Agents pharmacology, Anovulation
- Abstract
Ovulation is an integral part of women's menstrual cycle and fertility. Understanding the mechanisms of ovulation has broad implications for the treatment of anovulatory diseases and the development of novel contraceptives. Now, few studies have developed effective models that both faithfully recapitulate the hallmarks of ovulation and possess scalability. We established a three-dimensional encapsulated in vitro follicle growth (eIVFG) system that recapitulates folliculogenesis and produces follicles that undergo ovulation in a controlled manner. Here, we determined whether ex vivo ovulation preserves molecular signatures of ovulation and demonstrated its use in discovering novel ovulatory pathways and nonhormonal contraceptive candidates through a high-throughput ovulation screening. Mature murine follicles from eIVFG were induced to ovulate ex vivo using human chorionic gonadotropin and collected at 0, 1, 4, and 8 hours post-induction. Phenotypic analyses confirmed key ovulatory events, including cumulus expansion, oocyte maturation, follicle rupture, and luteinization. Single-follicle RNA-sequencing analysis revealed the preservation of ovulatory genes and dynamic transcriptomic profiles and signaling. Soft clustering identified distinct gene expression patterns and new pathways that may critically regulate ovulation. We further used this ex vivo ovulation system to screen 21 compounds targeting established and newly identified ovulatory pathways. We discovered that proprotein convertases activate gelatinases to sustain follicle rupture and do not regulate luteinization and progesterone secretion. Together, our ex vivo ovulation system preserves molecular signatures of ovulation, presenting a new powerful tool for studying ovulation and anovulatory diseases as well as for establishing a high-throughput ovulation screening to identify novel nonhormonal contraceptives for women., (© The Author(s) 2023. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
34. Thyroid hormone triiodothyronine does not protect ovarian reserve from DNA damage induced by X-ray and cisplatin.
- Author
-
Iwahata H, Kim SY, Iwahata Y, Suzuki N, and Woodruff TK
- Subjects
- Mice, Female, Rats, Animals, Triiodothyronine pharmacology, Triiodothyronine metabolism, X-Rays, Granulosa Cells metabolism, DNA Damage genetics, Cisplatin adverse effects, Ovarian Reserve genetics
- Abstract
Purpose: Cancer therapy can induce premature ovarian insufficiency, necessitating methods for preserving fertility in female cancer patients. However, the only accepted clinical practice for doing so is cryopreservation of embryos, unfertilized ova, and ovarian tissue, despite potential options such as in vitro maturation of follicles. Therefore, considerable interest has arisen in fertoprotective agents, with research on rat ovarian granulosa cells suggesting that triiodothyronine (T3) regulates an anti-apoptosis mechanism that protects the ovarian reserve from paclitaxel-induced DNA damage. In this study, we used postnatal day 5 mouse ovary to confirm the existence of T3 thyroid hormone receptor (THR), as well as to investigate the potential protective effects of T3 against cisplatin- and X-ray-induced apoptosis. We also tested the potential anti-apoptotic effect of T3 in the breast cancer cell line MDA-MB-231., Methods: We treated cultured mouse ovaries with varying concentration of T3 and 4 μM cisplatin and 0.2 Gy X-ray. Real-time PCR, histological analysis, immunoblot analysis, and immunofluorescence were performed to assess the potential anti-apoptotic effects of T3., Results: We confirmed that THR alpha and beta are expressed in the mouse ovary. T3 (0.1, 1, 10, 100 nM, and 1 µM) does not protect ovarian reserve from cisplatin- or X-ray-induced apoptosis or DNA damage. Similarly, it does not protect mouse granulosa cells and MDA-MB-231 cells from cisplatin- or X-ray-induced apoptosis., Conclusion: Our findings suggest that T3 is ineffective as a fertoprotective agent, and its candidacy as a potential agent to preserve fertility should be reconsidered., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
35. Zinc dynamics regulate early ovarian follicle development.
- Author
-
Chen YY, Chen S, Ok K, Duncan FE, O'Halloran TV, and Woodruff TK
- Subjects
- Animals, Female, Mice, Oocytes metabolism, Oogenesis physiology, Proteomics, Ovarian Follicle physiology, Zinc metabolism
- Abstract
Zinc fluctuations regulate key steps in late oocyte and preimplantation embryo development; however, roles for zinc in preceding stages in early ovarian follicle development, when cooperative interactions exist between the oocyte and somatic cells, are unknown. To understand the roles of zinc during early follicle development, we applied single cell X-ray fluorescence microscopy, a radioactive zinc tracer, and a labile zinc probe to measure zinc in individual mouse oocytes and associated somatic cells within early follicles. Here, we report a significant stage-specific increase and compartmental redistribution in oocyte zinc content upon the initiation of early follicle growth. The increase in zinc correlates with the increased expression of specific zinc transporters, including two that are essential in oocyte maturation. While oocytes in follicles exhibit high tolerance to pronounced changes in zinc availability, somatic survival and proliferation are significantly more sensitive to zinc chelation or supplementation. Finally, transcriptomic, proteomic, and zinc loading analyses reveal enrichment of zinc targets in the ubiquitination pathway. Overall, these results demonstrate that distinct cell type-specific zinc regulations are required for follicle growth and indicate that physiological fluctuation in the localization and availability of this inorganic cofactor has fundamental functions in early gamete development., Competing Interests: Conflict of interests The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
36. Follicle isolation methods reveal plasticity of granulosa cell steroidogenic capacity during mouse in vitro follicle growth.
- Author
-
Babayev E, Xu M, Shea LD, Woodruff TK, and Duncan FE
- Subjects
- 17-alpha-Hydroxypregnenolone metabolism, 17-alpha-Hydroxyprogesterone metabolism, Alginates metabolism, Alkaline Phosphatase metabolism, Androgens metabolism, Androstenedione metabolism, Animals, Carrier Proteins metabolism, Dehydroepiandrosterone metabolism, Estradiol metabolism, Female, Granulosa Cells metabolism, Humans, Inhibins metabolism, Mice, Pregnenolone metabolism, Theca Cells, Lyases metabolism, Progesterone metabolism
- Abstract
Follicles are the functional unit of the ovary and several methods have been developed to grow follicles ex vivo, which recapitulate key events of oogenesis and folliculogenesis. Enzymatic digestion protocols are often used to increase the yield of follicles from the ovary. However, the impact of these protocols on the outermost theca and granulosa cells, and thereby follicle function, is not well defined. To investigate the impact of enzymatic digestion on follicle function, we collected preantral follicles from CD1 mice either by enzymatic digestion (Enzy-FL) or mechanical isolation (Mech-FL) and compared follicle growth, steroidogenesis and cell differentiation within an encapsulated in vitro follicle growth system which maintains the 3D architecture of the oocyte and its surrounding somatic cells. Follicles were encapsulated in 0.5% alginate and cultured for 8 days. Compared with Enzy-FL, Mech-FL grew more rapidly and produced significantly higher levels of androstenedione, estradiol and progesterone. The expression of theca-interstitial cell marker genes, Cyp17a1, which encodes 17-hydroxylase/17, 20-lyase and catalyzes the hydroxylation of pregnenolone and progesterone to 17-hydroxypregnenolone and 17-hydroxyprogesterone, and the conversion of these products into dehydroepiandrosterone and androstenedione, and Star, which encodes a transport protein essential for cholesterol entry into mitochondria, were also higher in Mech-FL than in Enzy-FL. Mech-FL maintained an intact theca-interstitial layer on the outer edge of the follicle that phenocopied in vivo patterns as confirmed by alkaline phosphatase staining, whereas theca-interstitial cells were absent from Enzy-FL from the onset of culture. Therefore, preservation of the theca cell layer at the onset of culture better supports follicle growth and function. Interestingly, granulosa cells in the outermost layers of Enzy-FL expressed CYP17A1 by Day 4 of culture while maintaining inhibin α-subunit expression and a cuboidal nucleus. Thus, in the absence of theca-interstitial cells, granulosa cells have the potential to differentiate into androgen-producing cells. This work may have implications for human follicle culture, where enzymatic isolation is required owing to the density of the ovarian cortex., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
37. Broadening the educational pipeline: the global landscape of master of science programs in reproductive science and medicine.
- Author
-
Ataman-Millhouse LM, Monahan P, Willingham R, Vigone G, Soulakis M, Gadea J, Jiménez-Movilla M, Romar R, Cánovas S, Woodruff TK, and Duncan FE
- Subjects
- Humans, Reproduction, United States, Curriculum, Students
- Abstract
Reproductive health underpins overall health, and thus, research in reproductive science and medicine is essential. This requires a pipeline of trained scientists and clinicians, which is challenging given the relatively small size of the field. Educational programs outside the traditional doctorate or medical degrees are needed to generate and maintain a well-trained reproductive science and medicine workforce. Master's programs have gained traction as a viable way for students to receive educational value relative to their career goals. Our hypothesis is master's degree programs in the fundamental, applied, and allied health reproductive fields broadens the workforce and increases impact. An internet web search identified 73 programs that conferred an MS degree in the areas of animal science, clinical/embryology, and reproductive health/biology. These programs are spread across the globe in Europe (47%), North America (23%), Asia (14%), South America (7%), Oceania (5%), and Africa (4%). To evaluate global exemplars, we profiled the mission and structure, curriculum, and program impact of two established master's degree programs: the Master of Science in Reproductive Science and Medicine at Northwestern University in the United States and the Biology and Technology of Reproduction in Mammals at the University of Murcia in Spain. Elements of infrastructure and support, program connectivity, and alumni networks were analyzed for their role in the success of the programs. These two programs have formally trained >375 individuals, demonstrating master's degree programs in reproductive science are an important educational mechanism. The educational best practices shared here serve as templates for expanding training programs worldwide., (© The Author(s) 2022. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
38. Gender-diverse teams produce more novel and higher-impact scientific ideas.
- Author
-
Yang Y, Tian TY, Woodruff TK, Jones BF, and Uzzi B
- Subjects
- Gender Identity, Humans, Publications statistics & numerical data, Research standards, Research statistics & numerical data, Research Personnel statistics & numerical data
- Abstract
Science's changing demographics raise new questions about research team diversity and research outcomes. We study mixed-gender research teams, examining 6.6 million papers published across the medical sciences since 2000 and establishing several core findings. First, the fraction of publications by mixed-gender teams has grown rapidly, yet mixed-gender teams continue to be underrepresented compared to the expectations of a null model. Second, despite their underrepresentation, the publications of mixed-gender teams are substantially more novel and impactful than the publications of same-gender teams of equivalent size. Third, the greater the gender balance on a team, the better the team scores on these performance measures. Fourth, these patterns generalize across medical subfields. Finally, the novelty and impact advantages seen with mixed-gender teams persist when considering numerous controls and potential related features, including fixed effects for the individual researchers, team structures, and network positioning, suggesting that a team's gender balance is an underrecognized yet powerful correlate of novel and impactful scientific discoveries.
- Published
- 2022
- Full Text
- View/download PDF
39. Dynamic zinc fluxes regulate meiotic progression in Caenorhabditis elegans†.
- Author
-
Mendoza AD, Sue A, Antipova O, Vogt S, Woodruff TK, Wignall SM, and O'Halloran TV
- Subjects
- Animals, Fertilization, Mammals metabolism, Meiosis, Oocytes metabolism, Caenorhabditis elegans genetics, Caenorhabditis elegans metabolism, Zinc metabolism
- Abstract
Zinc influx and efflux events are essential for meiotic progression in oocytes of several mammalian and amphibian species, but it is less clear whether this evolutionary conservation of zinc signals is also important in late-stage germline development in invertebrates. Using quantitative, single cell elemental mapping methods, we find that Caenorhabditis elegans oocytes undergo significant stage-dependent fluctuations in total zinc content, rising by over sevenfold from Prophase I through the beginning of mitotic divisions in the embryo. Live imaging of the rapid cell cycle progression in C. elegans enables us to follow changes in labile zinc pools across meiosis and mitosis in single embryo. We find a dynamic increase in labile zinc prior to fertilization that then decreases from Anaphase II through pronuclear fusion and relocalizes to the eggshell. Disruption of these zinc fluxes blocks extrusion of the second polar body, leading to a range of mitotic defects. We conclude that spatial temporal zinc fluxes are necessary for meiotic progression in C. elegans and are a conserved feature of germ cell development in a broad cross section of metazoa., (© The Author(s) 2022. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
40. Correction to: A synopsis of global frontiers in fertility preservation.
- Author
-
Ataman LM, Laronda MM, Gowett M, Trotter K, Anvari H, Fei F, Ingram A, Minette M, Suebthawinkul C, Taghvaei Z, Torres-Vélez M, Velez K, Adiga SK, Anazodo A, Appiah L, Bourlon MT, Daniels N, Dolmans MM, Finlayson C, Gilchrist RB, Gomez-Lobo V, Greenblatt E, Halpern JA, Hutt K, Johnson EK, Kawamura K, Khrouf M, Kimelman D, Kristensen S, Mitchell RT, Moravek MB, Nahata L, Orwig KE, Pavone ME, Pépin D, Pesce R, Quinn GP, Rosen MP, Rowell E, Smith K, Venter C, Whiteside S, Xiao S, Zelinski M, Goldman KN, Woodruff TK, and Duncan FE
- Published
- 2022
- Full Text
- View/download PDF
41. A synopsis of global frontiers in fertility preservation.
- Author
-
Ataman LM, Laronda MM, Gowett M, Trotter K, Anvari H, Fei F, Ingram A, Minette M, Suebthawinkul C, Taghvaei Z, Torres-Vélez M, Velez K, Adiga SK, Anazodo A, Appiah L, Bourlon MT, Daniels N, Dolmans MM, Finlayson C, Gilchrist RB, Gomez-Lobo V, Greenblatt E, Halpern JA, Hutt K, Johnson EK, Kawamura K, Khrouf M, Kimelman D, Kristensen S, Mitchell RT, Moravek MB, Nahata L, Orwig KE, Pavone ME, Pépin D, Pesce R, Quinn GP, Rosen MP, Rowell E, Smith K, Venter C, Whiteside S, Xiao S, Zelinski M, Goldman KN, Woodruff TK, and Duncan FE
- Subjects
- Humans, Pandemics, COVID-19 epidemiology, Fertility Preservation, Neoplasms
- Abstract
Since 2007, the Oncofertility Consortium Annual Conference has brought together a diverse network of individuals from a wide range of backgrounds and professional levels to disseminate emerging basic and clinical research findings in fertility preservation. This network also developed enduring educational materials to accelerate the pace and quality of field-wide scientific communication. Between 2007 and 2019, the Oncofertility Consortium Annual Conference was held as an in-person event in Chicago, IL. The conference attracted approximately 250 attendees each year representing 20 countries around the world. In 2020, however, the COVID-19 pandemic disrupted this paradigm and precluded an in-person meeting. Nevertheless, there remained an undeniable demand for the oncofertility community to convene. To maintain the momentum of the field, the Oncofertility Consortium hosted a day-long virtual meeting on March 5, 2021, with the theme of "Oncofertility Around the Globe" to highlight the diversity of clinical care and translational research that is ongoing around the world in this discipline. This virtual meeting was hosted using the vFairs ® conference platform and allowed over 700 people to participate, many of whom were first-time conference attendees. The agenda featured concurrent sessions from presenters in six continents which provided attendees a complete overview of the field and furthered our mission to create a global community of oncofertility practice. This paper provides a synopsis of talks delivered at this event and highlights the new advances and frontiers in the fields of oncofertility and fertility preservation around the globe from clinical practice and patient-centered efforts to translational research., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
42. An Ovarian Steroid Metabolomic Pathway Analysis in Basal and Polycystic Ovary Syndrome (PCOS)-like Gonadotropin Conditions Reveals a Hyperandrogenic Phenotype Measured by Mass Spectrometry.
- Author
-
Gargus ES, Bae Y, Chen J, Moss KJ, Ingram AN, Zhang J, Montgomery NT, Boots CE, Funk WE, and Woodruff TK
- Abstract
Prior work has demonstrated that murine ovarian explants and isolated ovarian follicles can recapitulate human-like 28-day cycles in vitro with normal patterns of estradiol and progesterone secretion in response to gonadotropin stimulation. The objective of this study was to manipulate the gonadotropin stimulation protocol to mimic polycystic ovary syndrome (PCOS) and assess the resulting changes in ovarian steroidogenesis. A secondary aim of the study was to develop a high-throughput, sensitive, and specific liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay to measure seven steroid hormones (estrone, estradiol, progesterone, testosterone, androstenedione, dehydroepiandrosterone, and dihydrotestosterone) in conditioned culture media. Ovaries were harvested from 12-day-old CD-1 mice and cultured for 28 days, with ovulation induction on culture day 14. Media were supplemented human chorionic gonadotropin (hCG, a luteinizing hormone analog) and follicle stimulating hormone (FSH) at ratios of 1:0 (standard media), 1:1 (physiologic ratio), and 3:1 (PCOS-like ratio). Ovaries cultured in PCOS-like media displayed hyperandrogenism and impaired ovulation, two key features of a PCOS-like phenotype. Taken together, this first-of-its-kind presentation of hormone levels from single tissues creates a map of the enzymatic steps most acutely affected by gonadotropin dysregulation and may provide opportunities for assessing other potential insults in PCOS pathogenesis.
- Published
- 2022
- Full Text
- View/download PDF
43. Single-cell transcriptomics of staged oocytes and somatic cells reveal novel regulators of follicle activation.
- Author
-
Chen YY, Russo DD, Drake RS, Duncan FE, Shalek AK, Goods BA, and Woodruff TK
- Subjects
- Animals, Female, Granulosa Cells, Mammals, Mice, Oocytes, Ovary metabolism, Ovarian Follicle, Transcriptome
- Abstract
In Brief: Proper development of ovarian follicles, comprised of an oocyte and surrounding somatic cells, is essential to support female fertility and endocrine health. Here, we describe a method to isolate single oocytes and somatic cells from the earliest stage follicles, called primordial follicles, and we characterize signals that drive their activation., Abstract: Primordial follicles are the first class of follicles formed in the mammalian ovary and are comprised of an oocyte surrounded by a layer of squamous pre-granulosa cells. This developmental class remains in a non-growing state until individual follicles activate to initiate folliculogenesis. What regulates the timing of follicle activation and the upstream signals that govern these processes are major unanswered questions in ovarian biology. This is partly due to the paucity of data on staged follicle cells since isolating and manipulating individual oocytes and somatic cells from early follicle stages are challenging. To date, most studies on isolated primordial follicles have been conducted on cells collected from animal-age- or oocyte size-specific samples, which encompass multiple follicular stages. Here, we report a method for collecting primordial follicles and their associated oocytes and somatic cells from neonatal murine ovaries using liberase, DNase I, and Accutase. This methodology allows for the identification and collection of follicles immediately post-activation enabling unprecedented interrogation of the primordial-to-primary follicle transition. Molecular profiling by single-cell RNA sequencing revealed that processes including organelle disassembly and cadherin binding were enriched in oocytes and somatic cells as they transitioned from primordial to the primary follicle stage. Furthermore, targets including WNT4, TGFB1, FOXO3, and a network of transcription factors were identified in the transitioning oocytes and somatic cells as potential upstream regulators that collectively may drive follicle activation. Taken together, we have developed a more precise characterization and selection method for studying staged-follicle cells, revealing several novel regulators of early folliculogenesis.
- Published
- 2022
- Full Text
- View/download PDF
44. Zinc transporters ZIPT-2.4 and ZIPT-15 are required for normal C. elegans fecundity.
- Author
-
Sue AC, Wignall SM, Woodruff TK, and O'Halloran TV
- Subjects
- Animals, Fertility, Germ Cells metabolism, Humans, Phylogeny, Zinc metabolism, Caenorhabditis elegans genetics, Caenorhabditis elegans metabolism, Caenorhabditis elegans Proteins genetics, Caenorhabditis elegans Proteins metabolism, Carrier Proteins genetics, Carrier Proteins metabolism, Cation Transport Proteins genetics, Cation Transport Proteins metabolism
- Abstract
Purpose: The requirement of zinc for the development and maturation of germ lines and reproductive systems is deeply conserved across evolution. The nematode Caenorhabditis elegans offers a tractable platform to study the complex system of distributing zinc to the germ line. We investigated several zinc importers to investigate how zinc transporters play a role in the reproductive system in nematodes, as well as establish a platform to study zinc transporter biology in germline and reproductive development., Methods: Previous high throughput transcriptional datasets as well as phylogenetic analysis identified several putative zinc transporters that have a function in reproduction in worms. Phenotypic analysis of CRISPR-generated knockouts and tags included characterization of offspring output, gonad development, and protein localization. Light and immunofluorescence microscopy allowed for visualization of physiological and molecular effects of zinc transporter mutations., Results: Disruption of two zinc transporters, ZIPT-2.4 and ZIPT-15, was shown to lead to defects in reproductive output. A mutation in zipt-2.4 has subtle effects on reproduction, while a mutation in zipt-15 has a clear impact on gonad and germline development that translates into a more pronounced defect in fecundity. Both transporters have germline expression, as well as additional expression in other cell types., Conclusions: Two ZIP-family zinc transporter orthologs of human ZIP6/10 and ZIP1/2/3 proteins are important for full reproductive fecundity and participate in development of the gonad. Notably, these zinc transporters are present in gut and reproductive tissues in addition to the germ line, consistent with a complex zinc trafficking network important for reproductive success., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
45. Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II.
- Author
-
Salama M, Lambertini M, Christianson MS, Jayasinghe Y, Anazodo A, De Vos M, Amant F, Stern C, Appiah L, Woodard TL, Anderson RA, Westphal LM, Leach RE, Rodriguez-Wallberg KA, Patrizio P, and Woodruff TK
- Subjects
- Embryo, Mammalian, Female, Humans, In Vitro Oocyte Maturation Techniques, Surveys and Questionnaires, Breast Neoplasms complications, Fertility Preservation, Neoplasms
- Abstract
Purpose: As a further step to elucidate the actual diverse spectrum of oncofertility practices for breast cancer around the globe, we present and discuss the comparisons of oncofertility practices for breast cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II., Methods: We surveyed 39 oncofertility centers including 14 in limited resource settings from Africa, Asia & Latin America (Repro-Can-OPEN Study Part I), and 25 in optimum resource settings from the United States, Europe, Australia and Japan (Repro-Can-OPEN Study Part II). Survey questions covered the availability of fertility preservation and restoration options offered to young female patients with breast cancer as well as the degree of utilization., Results: In the Repro-Can-OPEN Study Part I & II, responses for breast cancer and calculated oncofertility scores showed the following characteristics: (1) higher oncofertility scores in optimum resource settings than in limited resource settings especially for established options, (2) frequent utilization of egg freezing, embryo freezing, ovarian tissue freezing, GnRH analogs, and fractionation of chemo- and radiotherapy, (3) promising utilization of oocyte in vitro maturation (IVM), (4) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, and stem cells reproductive technology as they are still in preclinical or early clinical research settings, (5) recognition that technical and ethical concerns should be considered when offering advanced and innovative oncofertility options., Conclusions: We presented a plausible oncofertility best practice model to guide oncofertility teams in optimizing care for breast cancer patients in various resource settings., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
46. Closing the loop on female fertility.
- Author
-
Woodruff TK
- Abstract
Discovery of a previously unidentified pituitary protein could provide innovative therapeutic options to regulate female fertility.
- Published
- 2021
- Full Text
- View/download PDF
47. A platform utilizing Drosophila ovulation for nonhormonal contraceptive screening.
- Author
-
Jiang K, Zhang J, Huang Y, Wang Y, Xiao S, Hadden MK, Woodruff TK, and Sun J
- Subjects
- Animals, Biological Assay, Chlorpromazine pharmacology, Dexmedetomidine pharmacology, Drug Approval, Female, Mice, Octopamine metabolism, Ovarian Follicle physiology, United States, United States Food and Drug Administration, Contraceptive Agents, Drosophila melanogaster physiology, Hormones metabolism, Ovulation physiology
- Abstract
A significant unmet need for new contraceptive options for both women and men remains due to side-effect profiles, medical concerns, and the inconvenience of many currently available contraceptive products. Unfortunately, the development of novel nonsteroidal female contraceptive medicine has been stalled in the last couple of decades due to the lack of effective screening platforms. Drosophila utilizes conserved signaling pathways for follicle rupture, a final step in ovulation that is essential for female reproduction. Therefore, we explored the potential to use Drosophila as a model to screen compounds that could inhibit follicle rupture and be nonsteroidal contraceptive candidates. Using our ex vivo follicle rupture assay, we screened 1,172 Food and Drug Administration (FDA)-approved drugs and identified six drugs that could inhibit Drosophila follicle rupture in a dose-dependent manner. In addition, we characterized the molecular actions of these drugs in the inhibition of adrenergic signaling and follicle rupture. Furthermore, we validated that three of the four drugs consistently inhibited mouse follicle rupture in vitro and that two of them did not affect progesterone production. Finally, we showed that chlorpromazine, one of the candidate drugs, can significantly inhibit mouse follicle rupture in vivo. Our work suggests that Drosophila ovulation is a valuable platform for identifying lead compounds for nonsteroidal contraceptive development and highlights the potential of these FDA-approved drugs as novel nonsteroidal contraceptive agents., Competing Interests: The authors declare no competing interest., (Copyright © 2021 the Author(s). Published by PNAS.)
- Published
- 2021
- Full Text
- View/download PDF
48. Metal ion fluxes controlling amphibian fertilization.
- Author
-
Seeler JF, Sharma A, Zaluzec NJ, Bleher R, Lai B, Schultz EG, Hoffman BM, LaBonne C, Woodruff TK, and O'Halloran TV
- Subjects
- Animals, Embryo, Nonmammalian metabolism, Embryo, Nonmammalian ultrastructure, Exocytosis physiology, Fertilization drug effects, Metals, Heavy pharmacology, Ovum drug effects, Ovum ultrastructure, Fertilization physiology, Metals, Heavy metabolism, Ovum metabolism, Xenopus laevis metabolism
- Abstract
Mammalian oocytes undergo major changes in zinc content and localization to be fertilized, the most striking being the rapid exocytosis of over 10 billion zinc ions in what are known as zinc sparks. Here, we report that fertilization of amphibian Xenopus laevis eggs also initiates a zinc spark that progresses across the cell surface in coordination with dynamic calcium waves. This zinc exocytosis is accompanied by a newly recognized loss of intracellular manganese. Synchrotron-based X-ray fluorescence and analytical electron microscopy reveal that zinc and manganese are sequestered in a system of cortical granules that are abundant at the animal pole. Through electron-nuclear double-resonance studies, we rule out Mn
2+ complexation with phosphate or nitrogenous ligands in intact eggs, but the data are consistent with a carboxylate coordination environment. Our observations suggest that zinc and manganese fluxes are a conserved feature of fertilization in vertebrates and that they function as part of a physiological block to polyspermy.- Published
- 2021
- Full Text
- View/download PDF
49. Reply: Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating.
- Author
-
Jackson-Bey T, Colina J, Isenberg BC, Coppeta J, Urbanek M, Kim JJ, Woodruff TK, Burdette JE, and Russo A
- Subjects
- Blastocyst, Epithelium, Fallopian Tubes, Female, Gene Expression, Humans, Luteal Phase, Pregnancy, Testosterone, Cilia, Follicular Phase
- Published
- 2021
- Full Text
- View/download PDF
50. Dental resins used in 3D printing technologies release ovo-toxic leachates.
- Author
-
Rogers HB, Zhou LT, Kusuhara A, Zaniker E, Shafaie S, Owen BC, Duncan FE, and Woodruff TK
- Subjects
- Animals, Female, Meiosis, Mice, Resins, Synthetic toxicity, Oocytes, Printing, Three-Dimensional
- Abstract
We recently engineered the first female reproductive tract on a chip (EVATAR), to enable sex-based ex vivo research. To increase the scalability and accessibility of EVATAR, we turned to 3D printing (3DP) technologies, selecting two biocompatible 3DP resins, Dental SG (DSG) and Dental LT (DLT) to generate 3DP microphysiologic platforms. Due to the known sensitivity of reproductive cells to leachable compounds, we first screened for toxicity of these biomaterials using an in vitro mammalian oocyte maturation assay. Culture of mouse oocytes in 3DP plates using conventionally treated DSG resin resulted in rapid oocyte degeneration. Oxygen plasma treatment of the surface of printed DSG resin prevented this degeneration, and the majority of the resulting oocytes progressed through meiosis in vitro. However, 57.0% ± 37.2% of the cells cultured in the DSG resin plates exhibited abnormal chromosome morphology compared to 19.4% ± 17.3% of controls cultured in polystyrene. All tested DLT resin conditions, including plasma treatment, resulted in complete and rapid oocyte degeneration. To identify the ovo-toxic component of DLT, we analyzed DLT leachate using mass spectroscopy. We identified Tinuvin 292, a commercial light stabilizer, as a major component of the DLT leachate, which resulted in a dose-dependent disruption of meiotic progression and increase in chromosomal abnormalities with oocyte exposure, showing significant ovo-toxicity in mammals. Severe reproductive toxicity induced by in vitro exposure to these 3D-printed resins highlights potential risks of deploying insufficiently characterized materials for biomedical applications and underscores the need for more rigorous evaluation and designation of biocompatible materials., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.